NZ193142A - Mercaptoacylpeptides and pharmaceutical compositions - Google Patents

Mercaptoacylpeptides and pharmaceutical compositions

Info

Publication number
NZ193142A
NZ193142A NZ193142A NZ19314280A NZ193142A NZ 193142 A NZ193142 A NZ 193142A NZ 193142 A NZ193142 A NZ 193142A NZ 19314280 A NZ19314280 A NZ 19314280A NZ 193142 A NZ193142 A NZ 193142A
Authority
NZ
New Zealand
Prior art keywords
compound
accordance
proline
alanyl
methyl
Prior art date
Application number
NZ193142A
Inventor
M A Ondetti
J Pluscec
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Publication of NZ193142A publication Critical patent/NZ193142A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052Val-amino acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Description

New Zealand Paient Spedficaiion for Paient Number 1 93142 193142 Priority Dsccjs)! ■ /"t ■ ■ ■ Complete Specification Filed: 17 Class: MVtti ) ??► PubHcatson Date: .. .2.4. ALIG. 1984- • P.O. Journal, No: ..
C0JCIA9 ; COflC6/04- Nl MUSHS i NEW ZEALAND PATENTS ACT, 1953 No.: Date: COMPLETE SPECIFICATION " mercaptoacyldipeptid '5 s " X/We, e.R. SQUIBB & SONS, INC., a corporation of Delaware having its offices at Lawrenceville-Princeton Road,' Princeton, New Jersey, United States of America, , ^ hereby declare the invention for whichjjl / we pray that a patent may be granted tOx££f/us, and the method by which it is to be performed, to be particularly described in and by the following statement: ~ " 1 - (followed by pag^. la) -lex — UAi&i- \ MERCAPTOACYLDIPEPTIDES Compounds having the formula ?2 R,—S—(CH,,) —CH—C—-A,—A0 1 2 n ^12 and alkyl esters and salts thereof, have useful hypotensive activity. In formula I, and throughout the specification, the symbols are as defined below.
R^ is hydrogen, alkanoyl, benzoyl or R-I ^ -S- (CH- ) —CH—C—A,—A0 ; 2. n || I 2 O R2 is hydrogen, alkyl, or phenylalkyl; n is 0 or 1; and A^ and each is an a-amino or a-imino acid residue joined through a peptide bond.
The term "alkyl", as used throughout the specification, refers to groups having 1 to 7 carbon atoms.
The term "alkanoyl", as used throughout the specification, refers to alkanoyl groups having 2 to 7 carbon atoms. Acetyl is the preferred alkanoyl group.
The a-amino and a-imino acid residues represented by A1 and A2 can be either naturally occurring or synthetic. Exemplary groups are proline, 4-hydroxyproline, 4,4-ethylenedioxyproline, 1«931 -HAr 4-methoxyproline, 4-thiazolidinecarboxylic acid, tryptophane, glycine, alanine, leucine, isoleucine and valine. As set forth above, the A-^ and A2 groups are linked by "a peptide bond"; i.e., the linkage -C-NH-, between the a-carboxyl group of the residue A^ and the a-amino or a-imino group of the group A2• The mercaptoacyldipeptides of formula I wherein is alkanoyl or benzoyl can be prepared 10 by acylation of a dipeptide having the formula S. ii H — A1—.—A2 or an alkyl ester derivative thereof, with a thio acid having the formula III R2 R' S (CH.) CH C OH 1 2 n I! o In formula III, and throughout the specification, the symbol R^ is alkanoyl or benzoyl. The above acylation can be accomplished using any one of the numerous techniques well known in the art. For example, the acylation can be affected in the 2 5 presence of a coupling agent such as a carbodiimide (of which dicyclohexylcarbodiimide is the most often used). Alternatively, the thio acid of formula III can be activated by formation of its mixed anhydride, symmetrical anhydride, acid 30 chloride or active ester or by the use of Woodward 1 931 flswr reagent K or N-ethoxycarbonyl-2-ethoxy-l,2-dihydroquinoline. For a more detailed discussion of various acylation techniques, reference is made to Methoden der organischen Chemie (Houben-Weyl), Vo.. XV, part II, page 1 et seq. (1974).
An alternative synthesis for the compounds of formula I wherein is alkanoyl or benzoyl comprises sequential acylation, as opposed to the previously described direct acylation, that is, the acylation of the amino acid "A^", with a mercaptoalkanoyl acid of formula III (using the procedure described above) to obtain a mercaptoalkanoyl amino acid having the formula I2 S (CH2)n CH 1 A1 - OH (iv) followed by acylation of the amino acid "A2" or alkyl ester thereof, with a mercaptoalkanoyl amino acid of formula IV. The acylation can be accomplished using any one of the well known techniques for coupling amino acids. For a review of these techniques reference should be made to Bodanszky and Ondetti, Peptide Synthesis, Interscience Publishers (1966).
Compounds of formula I wherein R^ is hydrogen can be prepared by ammonolysis or alkaline-hydrolysis of the corresponding compounds of formula I wherein R^ is alkanoyl or benzoyl which <1 Q ^ 1 •HA181" ( 931 can be obtained utilizing either of the procedures described aboveCompounds of formula I wherein p & R]_ is -S- (CH2) n-CH-C-A1-A2 can be prepared by , oxidation of the corresponding free thiol of formula I with iodine.
Alternatives to the above syntheses will be apparent to the practitioner of this invention. A. J. P. & S. H- H- For example, if an ester of^A^ A2 orftA2 is used in one of the above syntheses, the corresponding free acid can be obtained from the esterified product by acid or alkaline hydrolysis.
Mercaptoalkanoyl acids of formula III and mercaptoalkanoyl amino acids of formula IV, and methods for their preparation, are described in N-2. Specion <*•"* , , A J P &S15 t^ie literature; see> for example, ^United States Taw**" if-":?1' ' patonto 4 / 040 ,009, 4,105,77G and 4 ,053,651.
The compounds of this invention form basic salts with various inorganic and organic bases which are also within the scope of the invention. 2 0 Such salts include ammonium salts, alkali metal salts like sodium and potassium salts (which are preferred), alkaline earth metal salts like the calcium and magnesium salts, salts with organic bases e.g., dicyclohexylamine salt, benzathine, 2 5 N-methyl-D-glucamine, hydrabamine salts, salts with amino acids like arginine, lysine and the like. The nontoxic, physiologically acceptable salts are preferred, although other salts are also useful, e.g., in isolating or purifying the 3 0 product. 1 931 /HA181 ' The compounds of formula I, and the alkyl esters and salts thereof, are useful as hypotensive agents. They inhibit the conversion of the decapeptide angiotensin I to angiotensin II and, therefore, are useful in reducing or relieving angiotensin related hypertension. The action of the enzyme renin on angiotensinogen, a pseudo-globulin in blood plasma, produces angiotensin I. Angiotensin I is converted by angiotensin converting enzyme (ACE) to angiotensin II. The latter is an active pressor substance which has been implicated as the causative agent in various forms of hypertension in various mammalian species, e.g., rats and dogs. The compounds of this invention intervene in the angiotensinogen-* (renin) ^angiotensin !->• (ACE) ^-angiotensin II sequence by inhibiting angiotensin converting enzyme and reducing or eliminating the formation of the pressor substance angiotensin II. Thus by the administration of a composition containing one or a combination of compounds of formula I, angiotensin dependent hypertension in the species of mammal suffering therefrom is alleviated. A single dose, or preferably two to four divided daily doses, provided on a basis of about 0.1 to 100 mg. per kilogram of body weight per day, preferably about 1 to 50 mg. per kilogram of body weight per day is appropriate to reduce blood pressure. The substance is preferably administered orally, but parenteral routes such as the subcutaneous, intramuscular, intravenous or intraperitoneal routes can also be employed.
HT\\ R1 The compounds of formula I can be formulated for use in the reduction of blood pressure in compositions such as tablets, capsules or elixirs for oral administration or in sterile solutions or suspensions for parenteral administration.
About 10 to 500 mg. of a compound or mixture of compounds of formula I is compounded with a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, flavor, etc., in a unit dosage form as called for by accepted pharmaceutical practice. The amount of active substance in these compositions or preparations is such that a suitable dosage in the range indicated is obtained.
The following examples are specific embodiments of this invention.
-HA181-— Example 1 1- [N- (Acetylthioacetyl) glycyl] -L-proline Glycyl-L-proline (1.72 g) is taken into ml of IN sodium hydroxide with stirring in an ice bath. To this 5 ml of 2N sodium hydroxide is added followed by 1.13 g of chloracetyl chloride and the bath is removed. After three hours at room 10 temperature, thiolacetic acid (836 mg) and potassium carbonate (960 mg) in 10 ml of water is added and the reaction is stirred for about 16 hours at room temperature. The reaction is acidified with sulfonated polystyrene cation exchange resin, 15 eluted with water and concentrated to dryness in vauco. This was taken into acetic acid and the insolubles (melting point over 320°C) are filtered. The filtrate is concentrated to dryness in vacuo and 7:3 chloroform acetic acid is added. 20 The product is centrifuged and the supernate applied to a 60 g silica gel column and eluted with 7:3 chlorofo:rai: acetic acid yielding 1.0 g of the title compound. 2 5 Example 2 1-[N-(Mercaptoacetyl)glycyl]-L-proline 1-[N-(Acetylthioacetyl)glycyl]-L-proline 30 (1.0 g) is treated for thirty minutes under argon in a solution of 6 ml water and 6 ml concentrated sodium hydroxide. The solution is concentrated in vacuo, acidified with sulfonated polystyrene cation exchange resin, applied to a column of the 35 same and eluted with water. The 800 mg of material 1931 -OfiTZr- yielded therein (plus 200 mg from a previous preparation) is chromatographed on a 30 g column of silica gel with 7:3 chloroform: acetic acid.
This product (740 mg) is applied to an 85 ml column of diethylaminoethyl dextran anion exchange resin and eluted with a linear gradient of 0.005 M ammonium bicarbonate to 0.5 M ammonium bicarbonate (750 ml each). The product is converted to the free acid on sulfonated polystyrene cation exchange resin, and then treated with 7 ml of acetic acid and 350 ml of zinc dust with stirring under an argon blanket for six hours. The suspension is centrifuged, and the supernate concentrated to dryness in vacuo, taken into water and lyophilized. This is acidified with sulfonated polystyrene resin, applied to a column of the same and eluted with water yielding 365 mg of the title compound.
Analysis Calc. for: Cg H14N204S(.3)H20 Calc. for: C,42.95; H,5.68; N,11.13; S-12.72 Found : C,42.92; H,5.78; N,10.94; S-12.68 SH: Calc. -1.00; found -0.98 Example 3 t-Butyl ester of (S)-1-[3-(acetylthio)-2-methyl 1-oxopropyl]-L-prolyl-L-proline To a solution of 7.8 g of 1-[S-3-(acetylthio)-2-methyl-l-oxopropyl]-L-proline in 75 ml of dichloromethane is added 5.13 g of t-butyl-L-prolinate, and the solution is cooled to 5°C. To this solution is added (dropwise) a solution of dicyclohexylcarbodiimide in 50 ml of dichloromethane. The reaction is carried out at room temperature for about 16 hours. After the precipitate is removed, the resulting solution is successively washed with water, 5% sodium bicarbonate, water, 10% potassium bisulfate, and water, and then HA18\ 931 dried over sodium sulfate. The crude product (12 g) that is obtained after the solvent is removed, solidifies on standing. Recrystallization from ethyl acetate: pentane yields the title compound, melting point 104-106°C.
Example 4 1-(S-3-mercapto-2-methyl-l-oxopropyl)-L-prolyl-L- proline t-Butyl ester of 1- [S-3-(acetylthio)-2-methy 1-1-oxopropyl]-L-proline (12 g) is taken into 60 ml of redistilled trifluoroacetic acid and the resulting solution is allowed to stand at room temperature for 1 hour. Trifluoroacetic acid is removed in vacuo and the reisidue is carefully dried in high vacuo for 24 hours. The heavy oil is dissolved in 30 ml of methanol and to this is added 20 ml of concentrated ammonium hydroxide. The mixture is kept at room temperature for 1 hour, and the solvent is then removed in vacuo and the oil residue is dried and treated with 6 ml of dicyclohexylamine. The salt is treated with ether and an oil precipitates. The oil is taken into ethyl acetate and the solution is washed with 10% potassium bisulfate and then dried over sodium sulfate. After removal of the solvent, the residue is taken into methanol and the entire amount is adsorbed on silica gel. The solvent is removed and the silica gel containing the adsorbed product is applied to a silica gel column made up in chloroform. The column is eluted 1 93 with chloroform and the mercapto positive fractions are combined. The solvent is removed and the residue is lyophilized from water to yield 1.05 g of the title compound as a hygroscopic solid.
Analysis cal. for: C14H22N204S*1/2H20 Cal. for: C,51.99; H,7.17; N, 8.66; S, 9.92 Found: C,52.12; H,7.44; N,8.18; S,9.37 Neutralization equivalent: Calc., 323 found 341 Example 5 N-(Acetylthioacetyl)-L-valyl-L-proline A solution of t-butyloxycarbonyl-L-valyl-L-proline (3.1g) in trifluoracetic acid (20 ml) is kept at rocm temperature for 15 minutes, the solvent removed 15 in vacuo and the oily residue is dried in vacuo for several hours. The oil is taken into dimethyl-formamide (25 ml) and to this solution N-hydroxy-succinimide ester of acetylmercapto acetic acid (2.2 g) is added. The reaction is carried out at 2o pH 7.5 (adjusted with triethylamine) and at room temperature for 17 hours. After removal of the solvent, the residue is taken into ethyl acetate and the solution is washed successively with water, 10% potassium bisulfate,water, saturated sodium 2 5 bicarbonate, water and finally dried over sodium sulfate, yielding 4.8 g of the title compound as an oil.
Example 6 N-(Mercaptoacetyl)-L-valyl-L-proline 30 N-(Acetylthioacetyl)-L-valyl-L-proline (4.8 g) is taken into a mixture of 12 ml of methanol N- (Acetylthioacetyl)-L-valyl-L-proline (4.8 g) is taken into a mixture of 12 ml of methanol wtirr 1 93142 and 7.5 ml of concentrated ammonium hydroxide and the resulting solution is kept at room temperature for 1 hour. The pH is adjusted to 7 and methanol is removed in vacuo. The remaining aqueous layer is acidified to pH 2 with 2N hydrochloric acid and the solution is saturated with sodium chloride. The product is extracted with ethyl, acetate, the solution is dried over sodium sulfate and the solvent is removed iri vacuo, yielding 2 g of material, melting point 158-162°C. Recrystallization from ethyl acetate (with the addition of a small amount of methanol) yields the product, melting point 162-165°C. After drying a sample at 55°C for 2 hours the melting point is 190-192°C.
Example 7 ~ 0^3- (Acetylthio) -2-methvl-1 -oxopropvl 1 -t.-prolylglycine, ethyl ester Following the procedure of Example 3, but utilizing 10.4 g of 1-[S-3-(acetylthio)-2-methyl-1-oxopropyl]-L-proline, 100 ml of dichloromethane, 5.6 g of the ethyl ester of glycine (prepared from 5.58 g of the hydrochloride salt of the ethyl ester of glycine and 5.6 ml of triethylamine in 50 ml of dichloromethane) and 8.24 g of dicyclohexyl-carbodiimide, yields 11.2 g of the title compound as a viscous oil.
V93142 •HAi -12-Example 8 (S) -l-(3-Mercapto-2-methyl-l-oxopropyl)-L-prolylglycine, lithium salt 1-[S-3-(Acetylthio)-2-methyl-l-oxopropyl]-L-prolylglycine, ethyl ester (11.2 g) is taken into methanol (200 ml) to which an aqueous solution of potassium hydroxide (9 g in 40 ml of water) is 10 added. The hydrolysis is allowed to proceed at room temperature for two hours. The organic solvent is removed in vacuo and the aqueous residue is adjusted to pH 7.0. The product is extracted with ethyl acetate, the solution dried over sodium 15 sulfate and the solvent is removed in vacuo. The residue (3.5 g) is taken into water and the pH is adjusted to pH 2.0. The free acid is again taken into ethyl acetate using sodium chloride to decrease the solubility in water. The residue 20 after removal of the solvent, is lyophilized from water, yielding 2.16 g of the free base of the title compound. The entire amount was taken into water and the pH carefully adjusted to pH 7.0 using 0.05N lithium hydroxide. The solution is lyophilized to yield 2 5 105 0 mg of the title compound as a hygroscopic solid.
Analysis Calc. for: C^H^N^O^S • Li Calc: C,47.14; H,6.12; S,11.44; Li,2.48 Found: C,46.56; H,6.42; S,11.37; Li,2.43 V1 193142 » Example 9 (S)-1-(3-Mercapto-2-methyl-l-oxopropyl)- L-prolyl-L-alanine Following the procedure of Examples 3 & 4, but utilizing 7.8 g of 1-[S-3-(acetylthio)-2-methyl-l-oxopropyl]-L-proline, 75 ml of dimethyl-formamide, 6.2 g of dicyclohexylcarbodiimide, 4.2 g of the hydrochloride salt of the methyl ester of L-alanine and 4.2 "ml of triethylamine (pH 7.5-8.0), yields 8 g of material. This material is passed through a silica gel column using ethyl acetate as an eluant. Two fractions are obtained (Rf=0.76 and Rf=0.4, silica gel, ethyl acetate).
The slower moving fraction (2 g R^=0.4) is taken into potassium hydroxide/aqueous methanol (1.5 g potassium hydroxide in 7 ml of water and 35 ml of methanol) and the solution is kept at room temperature for 2 hours. The organic solvent is removed in_ vacuo and the aqueous layer is acidified to pH 2.0. After the addition of sodium chloride, the product is extracted five times with ethyl acetate. The solution is dried and the solvent is removed in vacuo. The solid residue is crystallized from hot.ethyl acetate, yielding 1 g of product, melting point 128-130°C. t 'SEP m Example 10 Acetylthioacetyl-L-valyl-L-tryptophan methyl ester A solution of 15 g of the methyl ester of t-butyloxycarbonyl-L-valyl-L-tryptophan in 150 ml of trifluoracetic acid and 15 ml of anisole is stirred for 1 hour under nitrogen. The solution is stripped in vacuo to an oily residue.
A solution of 4.83 g of acetylthioacetic acid and 6.18 g of hydroxybenzotriazole monohydrate in 120 ml of tetrahydrofuran is cooled to 0°C and yftBV 1 9314 7 treated with a solution of 8.16 g of dicyclo-hexylcarbodiimide in 60 ml of tetrohydrofuran. The mixture is stirred at 0°C for 0.5 hour 5 and then at room temperature for 1 hour. The precipitated urea is filtered and the filtrate is stripped in vacuo to a white solid. The active ester is dissolved in 90 ml of dimethyIformamide after which a solution of the above dipeptide methyl ester trifluoroacetic acid salt in 60 ml of dimethylformamide is added along with sufficient N-methyl morpholine to maintain the pH at 7.5 and the resultant mixture is stirred for 16 hours at room temperature. The reaction mixture is stripped in vacuo to an oil which is partitioned between ethyl acetate and water. The ethyl acetate phase is washed with 2N citric acid, water, saturated sodium bicarbonate solution, and water, and dried over sodium sulfate and stripped to a solid. The 20 material is crystallized from ethyl acetate: pentane to yield 10 g of the title compound, melting point 110-112°C.
Example 11 N-(Mercaptoacetyl)-L-valyl-L-tryptophan, lithium salt Acetylthioacetyl-valyl-tryptophan methyl ester (5.0 g) is dissolved in 52 ml of methanol 30 and a solution of 2.1 g of potassium hydroxide in .5 ml of water is added. The mixture is stirred under nitrogen at room temperature for 1.5 hours i r 93t a Si- after which the methanol is stripped in vacuo. The aqueous remainder is diluted with water, extracted with ethyl acetate and acidified to pH 2.0 with 6N hydrochloric acid. The solid is filtered, washed with water and dried yielding 3.4 g of material. The solid is chromatographed on a Sephadex LH-20 column using 7:3 methanol: water as eluant to yield 1.5 g of an oil. The oil is dissolved in 1:1 ethanol: water and adjusted to pH 7.0 with 0.IN lithium hydroxide. A small amount of insoluble material is removed by filtration and the filtrate is stripped in vacuo to an oil. The oil is dissolved in water and lyophilized to yield 1.5 g of a hygroscopic solid.
Analysis Calc. for: C,0H_„N O.S*Li lo 2. A 3 4 Calc.: C, 51.54; H,6.25; S,7.65; Li,1.65 Found: C, 51.94; H,6.03; S,7.28; Li,1.62 Neutralization Equivalent: Calc. 419; Found 413 Example 12 (S)-1-]3-(Acetylthio)-2-methyl-l-oxopropyl]-L-prolyl-D-alanine methyl ester To a solution of 1-[S-3-(acetylthio)-2-methyl-l-oxopropyl]-L-proline (7.8 g) in acetoni-trile (150 ml) carbonyldiimidazole (4.9 g) is added at 0°C. The mixture is stirred for 1 hour at this temperature after which the solution becomes almost clear and D-alanine methyl ester hydrochloride (4.2 g) is added. The pH-value is adjusted to 7.5-8.0 with triethylamine (4.2 ml) and the reaction mixture is stirred for 17 hours at room temperature. The precipitate and the solvent are removed and the oily residue is taken into ethyl acetate. The solution is successively washed with water, 0.1H HC1, water, saturated NafJCO^, HAi -16- water and dried. After removal of the solvent the remaining oil shows one spot on tic (silica gel., EtOAc and CHCl^:MeOH 9:1) at Rf=0.5 with a trace at Rf=0.75 (in ethyl acetate). Yield: 4 g. 5 Example 13 (S)-1-(3-Mercapto-2-methyl-l-oxopropyl)-L- prolyl-D-alanine (S)-[3-(Acetylthio)-2-methyl-l-oxopropyl]-L-prolyl-D-alanine methyl ester (4 g) is taken into 10 potassium hydroxide/agueous methanol (3 g of potassium hydroxide in 14 ml of water and 70 ml of methanol) and the solution is kept at room temperature for 2 hours. The product (2.1 g) is isolated using the procedure described in Example 9, m.p. 15 152-155°C. as a crystalline solid.
Analysis Calc. for: C12H20N2°4S Calc. for: C,49.98; H, 6 .99 ; S, 11.12 Found: C,50.02; H,7.24; S,10.90 Neutralization Equivalent: Calc. 288; found 284 t9314 2 Example 14 1-[N-(mercaptoacetyl)-L-alanyl]-L-proline To a solution of acetylthioacetic acid (1.3 g) and hydroxybenzotriazole (1.44 g) in tetrahydrofuran (39 ml), dicyclohexylcarbodiimide (2 g) is added and the mixture is stirred at 0°C for thirty minutes and at room temperature for one hour. The precipitate is removed by filtration, and to the filtrate is added L-alanyl-L-proline as its trifluoracetate salt (prepared from t-butyloxy-carbony1-L-alanyl-L-proline, 2.8 g, and trifluoroacetic acid). The pH is adjusted to 7.5-8.0 with ^Al8]r- 193142 N-methyImorpholine and the reaction is allowed to proceed at room temperature for about 16 hours. The solvents are removed in vacuo and the residue is dissolved in a mixture of methanol (18 ml) and 5 concentrated ammonium hydroxide (18 ml). After thirty minutes the mixture is concentrated in vacuo, the residue is dissolved in water and applied to a column of sulfonated polystyrene cation exchange resin eluting with water. This material is further 10 purified by silica gel chromatography (acetic acid:chloroform, 7:3) and crystallized from ethyl acetate, 850 mg, melting point 152-155°C[a]^=-128° (c=1.5, 50% aqueous MeOH).
Example 15 -• 1-[N-(Mercaptoacetyl)-L-alanyl]-L-thiazolidine-4-carboxylic acid Following the procedure of Example 14, but substituting the trifluoroacetic acid salt of L-alanyl-L-thiazolidine-4-carboxylic acid for the trifluoroacetic acid salt of L-alanyl-L-proline in the procedure of Example 14, yields the title, 25 compound.
Example 16 1- [N- (Mercaptoacetyl) -L-altanyl]-4-methoxy-L-proline Following the procedure of Example 14, but substituting the trifluoroacetic acid salt of L-alanyl-4-methoxy-L-proline for the trifluoroacetic acid salt of L-alanyl-L-proline, yields the title 35 compound. t 93 j Example 17 1-[N-(Mercaptoacety1-L-alanyl]-4-hydroxy-L-proline ■ Following the procedure of Example 14, but substituting the trifluoracetic acid salt of L-alanyl-4-hydroxy-L-proline for the trifluoro-acetic acid salt of L-alanyl-L-proline, yields the title compound.
Example 18 1-fN-(Mercaptoacetyl)-L-alanyl]-4, 4-ethylenedioxy-L-proline Following the procedure of Example 14, but substituting L-alanyl-4,4-ethylenedioxy-L-proline for the trifluoroacetic acid salt of L-alanyl-L-proline, yields the title compound.
Example 19 1-[N-(2-Mercaptopropanoyl)-L-alanyl]-L-proline Following the procedure of Example 14, but substituting 2-acetylthiopropionic acid for the 2-acetylthioacetic acid, yields the title compound, as a waxy solid, m.p. (47°) 54-65°C. (Dec.).
Analysis Calcd. for: C, , H..oN_0.S•1/2H-0 11 18 2 4 2 Calcd.: C,46.63; H,6.76; S,9.89 Found: C,46.50; H,6.58; S,9.78 SH Titration: 100% 193142 IIA101 -19-Example 20 1-[N-(3-Mercapto-l-oxopropyl-L-alanyl]-L-proline Following the procedure of Example 14, but 5 substituting 3-acetylthio-propionic acid for 2-acetylthioacetic acid, yields the title compound as a hygroscopic solid, m.p. (61°)75-84°C.
Analysis Calcd. for: • 0 . 75H20 Calcd: C,45.89; H,6.83; S,11.14 10 Found: C,45.75; H,6.62; S,10.98 SH Titration: 99.6% Example 21 •^5 1- [N- (2-Mercaptopropanoyl) -L-alanyl] -4- hydroxy-L-proline Following the procedure of Example 14, but substituting 2-acetylthiopropionic acid for 20 acetylthioacetic acid and the trifluoroacetic acid salt of L-alanyl-4-hydroxy-L-proline for the trifluoroacetic acid salt of L-alanyl-L-proline, yields the title compound.
Example 22 1-[N-(2-Mercaptopropanoyl)-L-alanyl] -L-thiazolidine-4-carboxylic acid Following the procedure of Example 14, but substituting 2-acetylthiopropionic acid for acetylthioacetic acid and the trifluoroacetic acid salt of L-alanyl-L-thiazolidine-4-carboxylic acid salt for the trifluoroacetic acid salt of 35 L-alanyl-L-proline, yields the title compound. 19314 HA181 ' " ■* ^ Example 23 1- [N- (2-Mercaptopropanoyl) -L-alanyl] -4-methoxy-L-proline Following the procedure of Example 14, but substituting 2-acetylthiopropionic acid for acetylthioacetic acid and the trifluoroacetic acid salt of L-alanyl-4-methoxy-L-proline for the 10 trifluoroacetic acid salt of L-alanyl-L-proline, yields the title compound.
Example 2 4 1-[N-(2-Mercaptopropanoyl)-L-alanyl]-4,4- ethylenedioxy-L-proline Following the procedure of Example 14, but substituting 2-acetylthiopropionic acid for 20 acetylthioacetic acid and L-alanyl-4,4-ethylenedioxy-L-proline for the trifluoroacetic acid salt of L-alanyl-L-proline, yields the title compound.
Example 25 1-[N-(2-Mercapto-3-phenylpropanoyl)-L-alanyl]-4- hydroxy-L-proline Following the procedure of Example 14, but substituting 2-acetylthio-3-phenylpropionic acid for acetylthioacetic acid and the trifluoroacetic acid salt of L-alanyl-4-hydroxy-L-proline ^ 193142 for the trif:luoroacetic acid salt of L-alanyl-L-proline, yields the title compound.
Example 26 .1-[N-(2-Mercapto-3-phenylpropanoyl)-L-alanyl]-L-thiazolidine-4-carboxylic acid Following the procedure of Example 14, 10 but substituting 2-acetylthio-3-phenylpropionic acid for acetylthioacetic acid and the trifluoroacetic acid salt of L-alanyl-L-thiazolidine-4-carboxylic acid for the trifluoroacetic acid salt of L-alanyl-L-proline yields the title compound.
Example 27 1-[N-(2-Mercapto-3-phenylpropanoyl)-L-alanyl]-4- methoxy-L-proline Following the procedure of Example 14, but substituting 2-acetylthio-3-phenylpropionic acid for acetylthioacetic acid and the trifluoro-acetic acid salt of L-alanyl-4-methoxy-L-proline for the trifluoroacetic acid salt of L-alanyl-L-proline, yields the title compound.
Example 28 1-[N-(2-Mercapto-3-propanoyl)-L-alanyl]-4, 4-ethylenedioxy-L-proline Following the procedure of Example 14, but substituting 2-acetylthio-3-phenylpropionic -2 2- 1 931 42 acid for acetylthioacetic acid and L-alanyl-4,4-ethylenedioxy-L-proline for the trifluoroacetic acid salt of L-alanyl-L-proline, yields the title compound.
Example 29 1- [N- (Mercaptoacetyl) -L-proline]-L-proline 10 Method A Benzyloxycarbonyl-L-prolyl-L-proline (3 g) is hydrogentated in a mixture of absolute ethanol (50 ml) and N-hydrochloric acid (7.5 ml) in the 15 presence of 10% palladium on charcoal. After five hours the catalyst is filtered off and the solvent is removed in vacuo. The residue is dissolved in a mixture of dimethylformamide (15 ml) and triethylamine (1.05 ml) and acetylthioacetic 20 acid N-hydroxysuccinimido ester (1.7 g) is added. After storage at room temperature for about 16 hours the solvents are removed in vacuo and the residue is chromatographed on a column of silica gel (benzene:hexane, 7:1). This material is 25 dissolved in trifluoroacetic acid (5 ml) and anisole (2 ml) and the solution is kept at room temperature for one hour. The reaction mixture is concentrated to dryness, and the residue is dissolved in 7.7 ml of N sodium hydroxide with 30 stirring under argon. After fifteen minutes the mixture is neutralized with sulfonated polystyrene rIIAlO'1" 19314 2 cation exchange resin, applied to a column of the same resin and eluted with water. The material obtained is crystallized from ethyl acetate and has a melting point 182-183°C.
Method B Dicyclohexylcarbodiimide (2.06 g) and 1-(acetylthioacetyl)—L-proline (2.3 g) are added to 10 a solution of L-proline t-butyl ester (1.7 g) and hydroxybenzotriazole (1.5 g) in dichloromethane (15 ml) chilled in an ice bath. After stirring at 5°C for about 16 hours, the resulting precipitate is filtered off and the filtrate is washed until 15 neutral. The organic layer is concentrated to dryness and the residue is purified by silica gel chromatography and crystallized from ether-hexane, yielding material with a melting point 95-98°C.
This material is deprotected by sequential treatment 20 with trifluoroacetic acid and sodium hydroxide as described in Method A. 193142 ■HAl 81— , I,, . . . Example 30 AeetHfTMi-paeerijl j p £S Aoefcylthioacotic-L-alanyl-L-tryptophan es*. ti <8^- methyl ester t - - L-alanyl-L-tryptophan-methyl ester acetate (2.5 grams) was dissolved in 20 ml of dimethyl-formamide and 2.0 grams of acetylthioacetic acid N-hydroxysuccinimide ester was added. The pH of the solution was adjusted to 7.5 with N-methyl morpholine and the mixture was stirred overnight 10 at room temperature. The solvent was removed in vacuo and the residual oil taken into ethyl acetate, washed with water, dried and stripped in vacuo to a foamy residue (3 grams). The residue was dissolved in ethyl acetate and applied to a 15 1.5 cm x 45 cm column containing 60 grams of Woelm basic alumina (activity I). Elution with ethyl acetate gave 1.6 grams of a foamy solid which gave one spot at Rf 0.69 on a silica gel thin-layer chromatograph, chloroform-methanol (3:1). 20 Example 31 N-[N-(Mercaptoacetyl)-L-alanyl]-L-tryptophan lithium salt A solution of the product of Example 30 (1.2 grams in 36 ml of methanol) was stirred with 6 ml 2 5 of IN sodium hydroxide solution under a nitrogen atmosphere for one-half hour at room temperature.
The reaction mixture was adjusted to pH 6 and the solvent was removed in vacuo. The residue was partitioned between ethyl acetate and saturated 30 sodium bicarbonate solution (1:1). The aqueous phase was washed with ethyl acetate, saturated with sodium chloride, acidified to pH 2.0 and extracted with ethyl acetate. The ethyl acetate extract was dried with sodium sulfate and stripped 35 in vacuo to a foamy residue. The residue was 193142 HA101 dissolved in a 50% aqueous ethanol solution and the pH adjusted to 7 with IN lithium hydroxide solution. The solution was stripped to dryness and the residue taken into water and lyophilized to an off-white solid (390 mg).
Analysis Calcd. for: C,rHnoN_0.S•Li•2H^O 16 18 3 4 2 Calcd: C,49.11; H,5.67; N,10.73; S,8.18 Found: C,98.78; H,5.07; N,10.41; S,7.85 Example 32- (S)-1-(3-Mercapto-2-methyl-l-oxopropyl)- L-prolyl-B-alanine A. 3.06 grams of B-alanine-ethyl ester/hydro-chloride and 2.82 ml of triethylamine were/added to a solution of 5.2 grams of 1-[S-3-acetyl£nio)-2- methyl-l-oxopropyl]-L-proline and 3.24/grams of carbonyldiimidazole at 0°C. and the Resultant mixture was stirred overnight at room temperature.
The reaction mixture was stripped of solvent and the residue was extracted with/ethyl acetate. The 2 0 ethyl acetate extract was then washed with water, IN hydrochloric acid solution, water again, saturated sodium bicarbonate solution and water again and then dried /ver sodium sulfate and stripped to a cleai/oil (3.4) grams. This material 25 was proven by spectral analysis to be (S)—1— (3 — acetylthio-2-methyl-l-oxopropyl)-L-prolyl-B-alanine and was usecr as such in the next step.
B. 2>. 4 grams of the material from step A was dissolved in a solution of 43 ml of methanol and 1.7 arams of potassium hydroxide in 8.6 ml of water was/added. The mixture was stirred for one hour aY room temperature, 5 0 ml of water was then added ^and the methanol was removed. The aqueous remainder 'was acidified to- pll 2.0 with dilute hydrochloric acid 19314 2 I 1 f|1 ha j. u x—1 Thc oolvont was then removed in vacuo and the residue was extracted with methanol. After drying, the methanol solvent was removed to leav^an oil (3.2 grams) which was chromatograph^eKon an LH-20 5 Sephadex column and eluted with^a methanol-water ^ j p ^ solution (1:9) to give 1. l^gr ams of the titled compound as a clear oiJt< TLC one spot, Rf 0.65 silica gel, mettmm51.
Analys>s^Calcd. for: C^2H20N2^4^ 10 Calcd. for: C,49 .99; H,6.99; N,9.71 Found: r,AQ r1- h,7 ?q- m,p f,l a. j. p. & s. Example 3r?r ?l (R) -1- [N- (2-mercapto-l-oxo-3-phenyl- propyl) -L-alanyl] -L-proline A. (R)-2-acetylthio-3-phenyl-propionic acid Sodium nitrite (32.75 grams) was added to a cooled solution of L-phenylalanine (51 grams) and potassium bromide (125 grams) in 620 ml of 25 N sulfuric acid over a period of one hour while 20 maintaining the temperature of the reaction mixture at 0°C. The reaction mixture was stirred for one additional hour at 0° and then for one hour at room temperature. The reaction mixture was then extracted with ether and the ether extract was dried over 25 sodium sulfate. The ether was removed to leave (S)-2-bromo-3-phenyl-propionic acid as an oily residue (44.9 grams) which was distilled at 142-144°C (0.25 mm.Hg).
A mixture of thioacetic acid (8.7 ml) and 30 potassium hydroxide (6.8 g) in 225 ml of acetonitrile was stirred for one hour and fifteen minutes at room temperature. The mixture was cooled in an ice bath and 25.3 grams of (S)-2-bromo-3-phenyl-propionic acid in 25 ml of acetonitrile was added over ten 35 minutes. After stirring for five hours, the reaction 193142 IIA1 81 mixture was filtered and the solvent removed in vacuo and the oily residue redissolved in ethyl acetate and dried, and the solvent removed to yield 24 grams of crude (R)-2-acetylthio-3- phenyl-propionic acid. The crude material was purified via formation of the dicyclohexylamine salt using ether as a crystallizing solvent. The 25 free acid, [a] = +62° (C=2.8, chloroform) was regenerated with hydrochloric acid and extraction 10 with ethyl acetate.
B. R-(2-acetylthio-3-phenyl)propionyl-L-alanyl-L-proline The above product is prepared by reacting the (R)-2-acetylthio-3-phenylpropionic acid from part 15 (A) above with L-alanyl-L-proline according to the procedure of Example 14, m.p. (124°)135-138°C, [a]^= -23° (C=1.4, chloroform).
C. R-l-[N-(2-mercapto-l-oxo-2-phenylpropyl)-L-alanyl-L-proline By continuing the procedure of Example 14 with the material from part (B) above, and using sodium hydroxide instead of ammonium hydroxide, the titled product is obtained as a foamy solid, [a]^= -78.4° (C-l.l, chloroform).
Analysis Calcd. for: C._HooN„0.S"2Ho0 17 22 2 4 2 Calcd. C,52.83; H,6.78; N,7.25; S,8.30 A. J. P. & S. Found: C, 52.54; H,6.26; N,7.01 S, 8.16 Example •3-4' ^"3 (S)-1[N-(2-mercapto-l-oxo-3-phenylpropyl)- L-alanyl-L-proline A. (S)-2-acetylthio-3-phenylpropionic acid A J P. & S. Following the procedure of part (A) of Example Jri and substituting D-phenylalanine for L-phenyl- -&f?.im alanine, m.p. 146-147°C from ethyl acetate as the dicyclohexylamine salt. The free acid was regenerated t 931 4 with hydrochloric acid and extracted with ethyl 25 acetate, [alD = -70.1° (Crl.91, chloroform) B. (S)-(2-acetylthio-3-phenyl)propionyl-L-alanyl-L-proline By reacting the material from part (A) above with L-alanyl-L-proline according to the procedure A. J. P. & S. of Example .J^(B) , the above titled compound is obtained ivii- as oily residue which on trituration with ethyl ether and hexane solidifies, m.p. 161-163°C, [ot]2^= -10.9.6° 10 (C-1.5, chloroform).
C. (S)-1-[N-(2-mercapto-l-oxo-3-phenylpropyl)-L-alanyl-L-proline The above titled product is obtained by treating A. J. P. & S. the material from part (B) above according to the procedure of Example lr$\C) , as a foamy solid, [a]^= -82.7° (C=1.5, chloroform).
Analysis Calcd. for ' H2° Calcd: C,55.42; H,6.56; N,7.60; S,8.70 Found: C,55.25; H,6.18; N,7.36; S,8.43 20 SH titration: 99.1% A. J. P. & S. Example N-[N-[2-(Mercaptomethyl)-1-oxo-3-phenyl- propyl]glycyl]-L-arginine A. N-[2-[(Acetylthio)methyl]-1-oxo-2-phenyl-25 propyl]glycine A 13 gram (0.067 mole) sample of benzyl malonic acid was mixed with 7.6 grams (0.068 mole) of 40% aqueous dimethylamine and 5.4 grams (0.068 mole) of 37% formalin in 150 ml of water. The voluminous 30 solid which formed in 15 minutes was filtered after 2 hours, washed with water and dried partially in air to give 20.8 grams (theory=16.8 grams). The solid was melted in a 170° oil bath and heated for 10 minutes, until amine evolution had stopped and 35 bubbling had virtually ceased. The cooled product, 1 931 IIA101— a mobile liquid, was acidified with 10% KHSO^, extracted with hexane, dried (Na2S04) and evaporated to give 6.3 grams of solid. The aqueous filtrates from the Mannich reaction were allowed to stand overnight and were then heated at 100°C on a steam cone until bubbling ceased (2 hours).
Cooling, acidification and extraction as above gave another 1.2 grams of solid for a total of 7.5 grams (75%) of benzylacrylic acid.
A 6.2 gram (0.04 mole) sample of benzylacrylic acid in 350 ml of dichloromethane was treated with 5.4 grams (0.04 mole) of ethyl glycinate hydrochloride and 3.9 grams (0.04 mole) triethylamine. The mixture was cooled in ice and 7.9 grams (0.04 mole)dicyclohexyl carbodiimide was added. The mixture was stirred at 25°C overnight, then filtered. The filtrates were shaken with aqueous bicarbonate, 10% KHSO^, then water, and dried (Na2SC>4) and evaporated to an oil. This was taken up in 200 ml of methanol and treated with excess 10% NaOH. The mixture was heated for 15 minutes on a steam cone, then evaporated to an aqueous slurry. This was filtered and the filtrates extracted with ether. The aqueous was acidified (10% HC1) and extracted with chloroform, the extracts dried (Na2SO^) and evaporated to an oil, 7.3 grams (80%).
Thiolacetic acid (10 ml) was added to 3.2 grams (0.014 mole) of the glycine derivative and the resulting solution was evaporated the next day in vacuo. Trituration with isopropyl ether gave a near-white solid, 2.9 grams. Recrystallization from ethyl acetate-hexane gave 2.5 grams (60%), m.p. 97-101°C.
Anal. Calcd. for: C,„H,_NO..S 14 17 4 Calcd. for: C,56.93; H,5.80; N,4.74; S,10.85 Found: C,56.68; H,5.87; N,4.77; S,10.81 193142 -HMrfrl— B. N-[N-[2-[(Acetylthio)methyl]-l-oxo-3-phenylpropyl]glycyl-L-arginine A 0.3 gram sample (1 mmole) of the product of part (A) was dissolved in 25 ml of dry tetrahydro-5 furan, 0.11 g (1.1 mmole) of triethylamine was added and the mixture cooled to 0°C. Then 0.11 g (1 mmole) of ethyl chloroformate was added, and after the mixture was stirred for 4 0 minutes at 0°, it was filtered into a solution of 0.17 g (1 mmole) 10 of arginine in 10 ml of water. After stirring at 2 5°C overnight the mixture was evaporated to an aqueous mixture which was diluted to 3 0 ml with water and. extracted gently (to avoid emulsions) with ethyl acetate. The aqueous was chromatographed 15 on 50 g of Avicel in water, taking 25 ml fractions.
The two Sakaguchi positive fractions were combined and filtered through a nuclepore polycarbonate filter and lyophilized to give 0.3 g (63%) white powder, m.p. 105-120°, which, after drying at 20 95-100°C for 6 hours in vacuo analyzed correctly for the presence of 1.5 moles of water.
Anal. Calcd. for: C2qH2 gN^-Oj-S • 1. 51^0; Calcd. for: C,50.19; H,6.74; N,14.63; S,6.70 Found: C,50.38; H,6.56; N,14.95; S,6.50 25 C. N-[N-[2-(Mercaptomethvl)-1-oxo-3-phenyl- propyl]glycyl]-L-arginine A 0.5 g (1.1 mmole) sample of the product of Part (B) was cooled in ice and treated with 4 ml of conc. NH^OH under argon. After stirring for 3 0 1 hour, the sample was evaporated in vacuo to a glass. This was triturated with 25 ml of acetonitrile for 2 hours, then the solvent was decanted and replaced with fresh solvent and stirred for 2 1/2 days under argon. The resulting white solid 35 was filtered and washed with acetonitrile and ether.

Claims (34)

1 93~1 4 2~ <^IA101 ' -31- Drying at 45° over KOH, P2<~>5 an<^ paraflin at 0.01 mm Hg overnight to give 0.25 g (55%) of solid, m.p. 120-137°. Anal. Calcd. for : C^gl^yN^O^S • 1. 75 H^O 5 Calcd. for: C,49.02; H,6.97; N,15.88; S ,7.27 Found: C,48.89; H,6.67; N,16.17; S,7.28 193142 -HA181 -32- rfnAT//WE CLAIM IS: What jg olaiTnpH—is-?
1. A compound having the formula R, Rn —s— (CH2 ) —CH—C—An — A0 , 1 2 0 or an alkyl ester or a salt thereof, wherein R^ is hydrogen, alkanoyl, benzoyl or R, I 2 -S- (CH. ) ~~-CH—C—-A, —; 2 n || 1 2 0 R2 is hydrogen, alkyl or phenylalkyl; n is 0 or 1; and A^ and A2 each is an a-amino or a-imino acid residue joined through a peptide bond.
2. A compound in accordance with claim 1 wherein R^ is hydrogen.
3. A compound in accordance with claim 1 wherein R1 is alkanoyl.
4. A compound in accordance with claim 1 wherein R^ is Ro I2 -S- (CH~ ) —CH—C—A,—A„ 2 n || 1 2 . 0
5. A compound in accordance with claim 1 wherein R2 is hydrogen.
6. A compound in accordance with claim 1 wherein R2 is alkyl.
7.. A compound in accordance with claim 1 wherein R2 is phenylalkyl. -33- 193142
8. A compound in accordance with claim 1 wherein n is 0.
9. A compound in accordance with claim 1 wherein n is 1.
10. A compound in accordance with claim 1 wherein A^ is an o(-amino acid residue and A2 is an cJv-imino acid residue.
11. A compound in accordance with claim 10 wherein A2 is an L-proline residue.
12. A compound in accordance with claim 1 wherein A^ and A2 each is independently a proline, 4-hydroxyproline, 4,4-ethylenedioxyproline, 4-methoxyproline, 4-thiazolidinecarboxylic acid, tryptophan, glycine, alanine, leucine, isoleucine or valine residue.
13. The compound in accordance with claim 1, 1-/ N-(acetylthioacetyl)glycyl_/-L-proline.
14. The compound in accordance with claim 1, 1-/ N-(mercaptoacetyl)glycyl_/-L-proline.
15. The compound in accordance with claim 1, t-butyl ester of (S)-1-/ 3-(acetylthio)-2-methyl-l-oxo-propyl_7-L-prolyl-L-proline.
16. The compound in accordance with claim 1, (S)-1-(3-mercapto-2-methyl-l-oxopropyl)-L-prolyl-L-proline.
17. The compound in accordance with claim 1, N-(acetylthioacetyl)-L-valyl-L-proline.
18. The compound in accordance with claim 1, N-(mercaptoacetyl)-L-valyl-L-proline.
19. The compound in accordance with claim 1, (S)-1-/3-(acetylthio)-2-methyl-l-oxopropyl_7-L-prolyl-glycine, ethyl ester. -34- 193142
20. The compound in accordance with claim 1, (S)-1-(3-mercapto-2-methyl-l-oxopropyl)-L-prolyl-glycine, lithium salt.
21. The compound in accordance with claim 1, (S)-1-(3 - mercapto-2-methyl-l-oxopropyl)-L-prolyl-L-alanine.
22. The compound in accordance with claim 1, N-(acetylthioacetyl ) -L-valyl-L-tryptophan methyl ester.
23. The compound in accordance with claim 1, N-(mercaptoacetyl)-L-valyl-L-tryptophan, lithium salt.
24. The compound in accordance with claim 1, (S)-1-/ 3-(acetylthio)-2-methyl-l-oxopropyl_7-L-prolyl-D-alanine methyl ester.
25. The compound in accordance with claim 1, (S)-1-(3-mercapto-2-methyl-l-oxopropyl)-L-prolyl-D-alanine.
26. The compound in accordance with claim 1, 1-/ N-(mercaptoacetyl)-L-alanyl 7~L-proline.
27. The compound in accordance with claim 1, 1-/ N-(3-mercapto-l-oxopropyl)-L-alanyl_7-L-proline.
28. The compound in accordance with claim 1, N-(acetylthioacetyl)-L-alanyl-L-tryptophan methyl ester. 193142 -35-
29. The compound in accordance with claim 1, N-/ N-(mercaptoacetyl)-L-alanyl_7-L-tryptophan, lithium salt. A j p & 5 -3-£H Tho compound in accordance with claim 1; it-ll-?"1" -fS-)—1—(3 acetylthio—2 methyl 'l-oxo-propyl) -Ir prolyl-^ alanino^. - -3-t? Tho compound in acoordanoo with claim -i-y J* P• St « n-d-fv ■(£) .l-(3 morcapto 2 methyl—1 oitopropyl)—L prolyl-p- alanino> 3o ^•jL' ^ J&Z. The compound in accordance with claim 1, .ft (R)-N-(2-acetylthio-3-phenylpropionyl)-L-alanyl-L-proline . A. J. P. &S. 3| /l-li-fv -3-3~. The compound in accordance with claim 1, (R) -I-/ N-(2-mercapto-l-oxo-3-phenyl-propyl)-L-alanyl_7_L- proline. A. J. P. & S. /I-u-fv- }*" W / J-4". The compound in accordance with claim 1, .(/&&* • (gj _N_ (2-acetylthio-3-phenylpropionyl) -L-alanyl-L- proline. J. P. & S. tl-K-f'f 33 •^r- T^e compound m accordance with claim 1, (S)— 1—/ N-(2—mercapto—1—oxo—3—phenyl—propyl)—L—alanyl_7— L-proline. Vs- "''' A method for reducing blood prooouro in i. Y. St. ^1 " mammals which comprises administeJHHno-: Eo a mammal in " need thrrrnf, in i rfiTtrr imnnnt of a compound havinq mc....... -——— ___ -36- 193142 ■m . &s. _EL g—in ht r n or an alkyl ester or a physiologically acceptable salt thereof, wherein R1 is hydrogen, alkanoyl^/Kenzoyl or S — (ch2) n a. j. p. & s. II -M- M: .. J. p. & s. R^xis hydrogen, alkyl or phenylalkyl; 'n is 0 or 1; and A1 and A2 each is an e<-amino or c^-imino acid fuAiduc—joined through a papLide bund .— ■ _ A process for preparing a compound having the formula R~ R., -A, (CH0) —CH C — A, 2 n || 1 2 0 or an alkyl ester or a salt thereof, wherein R^ is hydrogen, alkanoyl, benzoyl or R ' • •S (CH0) CH C
2. n II 0 A1 A2' R 2 is hydrogen, alkyl or phenylalkyl; n is 0 or 1; and A^ and A^ each is an -amino or e^-imino acid residue joined through a peptide bond, characterized by acy-" lating, directly or sequentially, a dipeptide of the [*,-9 SEP J9f 113/4-2- 37 - formula H-A1-A2 or an alkyl ester derivative thereof with a thio acid having the formula r2 R'X — S (CH2^ri CH C00H wherein R^ is alkanoyl or benzoyl, to form products wherein R^ is alkanoyl or benzoyl, and subjecting said products to conventional hydrolysis to form products wherein R^ is hydrogen, and oxidizing said products wherein Rj is hydrogen to form products wherein R^ is R2 0 s (CH2)n CH— C Ax A2f \ and forming salts of the above products wherein the -A2 group terminates in a carboxylic acid group by reaction with an organic or inorganic base.
35. A compound as claimed in any one of claims 1 to 33 substantially as hereinbefore described with reference to any of the examples.
36. A process as claimed in claim 34 when performed substantially as hereinbefore described.
37. A product of a process as claimed in claim
34. DATED THIS^"^ DAY OF x ^ 19<SCp _ A. J. PARK & SON PER Sn\\ AQENTS for the applicants 'tAPRwyf
NZ193142A 1979-04-02 1980-03-17 Mercaptoacylpeptides and pharmaceutical compositions NZ193142A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2570179A 1979-04-02 1979-04-02

Publications (1)

Publication Number Publication Date
NZ193142A true NZ193142A (en) 1984-08-24

Family

ID=21827594

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ193142A NZ193142A (en) 1979-04-02 1980-03-17 Mercaptoacylpeptides and pharmaceutical compositions

Country Status (22)

Country Link
JP (1) JPS55133345A (en)
AT (1) AT373577B (en)
AU (1) AU537592B2 (en)
BE (1) BE882601A (en)
CH (1) CH645092A5 (en)
DE (1) DE3012140A1 (en)
DK (1) DK140480A (en)
ES (1) ES8104200A1 (en)
FR (1) FR2453135A1 (en)
GB (1) GB2045771B (en)
GR (1) GR67752B (en)
HU (1) HU181087B (en)
IE (1) IE49653B1 (en)
IT (1) IT1147332B (en)
LU (1) LU82316A1 (en)
NL (1) NL8001675A (en)
NO (1) NO150360C (en)
NZ (1) NZ193142A (en)
PH (1) PH22024A (en)
PT (1) PT71044A (en)
SE (1) SE8002512L (en)
ZA (1) ZA801527B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5692848A (en) * 1979-12-27 1981-07-27 Dainippon Pharmaceut Co Ltd Preparation of 1- 3-lower alaknoylthio-2-methylpropanoyl prolylphenylalanine
JPS56139455A (en) 1980-04-02 1981-10-30 Santen Pharmaceut Co Ltd Sulfur-containing acylaminoacid
US4336950A (en) * 1980-09-08 1982-06-29 John Zepkowski Sled
US4462943A (en) * 1980-11-24 1984-07-31 E. R. Squibb & Sons, Inc. Carboxyalkyl amino acid derivatives of various substituted prolines
JPS57142967A (en) * 1981-02-27 1982-09-03 Dainippon Pharmaceut Co Ltd N-(acylthioalkanoyloxy)succinimide and its use
US4512979A (en) * 1981-03-23 1985-04-23 Merck & Co., Inc. Dipeptides containing thialysine and related amino acids as antihypertensives
US4382081A (en) * 1981-06-12 1983-05-03 E. R. Squibb & Sons, Inc. Inhibitors of mammalian collagenase
IT1195287B (en) * 1981-11-05 1988-10-12 Ausonia Farma Srl THIAZOLIC DERIVATIVE, PROCEDURE FOR ITS PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS
US4434151A (en) * 1982-11-08 1984-02-28 Medi-Physics, Inc. Bifunctional chelating agents
DE3243369A1 (en) * 1982-11-24 1984-05-24 Basf Ag, 6700 Ludwigshafen BIS- (BENZOYLTHIO) CARBONIC ACIDS, THEIR PRODUCTION AND USE FOR THE PRODUCTION OF ACTIVE SUBSTANCES
US4642355A (en) * 1984-02-24 1987-02-10 Otsuka Pharmaceutical Factory, Inc. Proline derivatives
US4560506A (en) * 1984-05-25 1985-12-24 E. R. Squibb & Sons, Inc. Mercaptocycloalkylcarbonyl and mercaptoarylcarbonyl dipeptides
DE3432307A1 (en) * 1984-09-03 1986-04-10 Boehringer Ingelheim KG, 6507 Ingelheim AMINO ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS
DE3436569A1 (en) * 1984-10-05 1986-04-10 Boehringer Ingelheim KG, 6507 Ingelheim AMINO ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS
WO1987002986A1 (en) * 1985-11-15 1987-05-21 The Upjohn Company Novel renin inhibiting polypeptide analogs containing s-aryl-d- or l- or dl-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties
US4894437A (en) * 1985-11-15 1990-01-16 The Upjohn Company Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties
JPH0662671B2 (en) * 1986-01-17 1994-08-17 株式会社大塚製薬工場 Proline derivative
DE69130605T2 (en) * 1991-02-27 1999-05-20 Lacer Sa Antihypertensive N- (alpha-substituted pyridyl) carbonyl dipeptides
FR2679564A1 (en) * 1991-07-23 1993-01-29 Inst Nat Sante Rech Med NOVEL ACYLMERCAPTOALCANOLDIPEPTIDES, THEIR PREPARATION AND THE COMPOSITIONS CONTAINING THEM.
US5504080A (en) * 1992-10-28 1996-04-02 Bristol-Myers Squibb Co. Benzo-fused lactams
GB9310075D0 (en) * 1993-05-17 1993-06-30 Fujisawa Pharmaceutical Co New mercapto-amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
US7390789B2 (en) * 2005-09-13 2008-06-24 William H Simmons Thio-containing inhibitors of aminopeptidase P, and compositions thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS559058A (en) * 1978-07-06 1980-01-22 Dainippon Pharmaceut Co Ltd 1-(3-mercapto-2-methylpropanoyl)prolyl amino acid derivative

Also Published As

Publication number Publication date
FR2453135A1 (en) 1980-10-31
HU181087B (en) 1983-05-30
AU5638080A (en) 1980-10-09
PT71044A (en) 1980-05-01
AU537592B2 (en) 1984-07-05
NO800931L (en) 1980-10-03
IT8021110A0 (en) 1980-04-01
ATA179480A (en) 1983-06-15
FR2453135B1 (en) 1983-06-17
SE8002512L (en) 1980-10-03
GR67752B (en) 1981-09-18
JPS55133345A (en) 1980-10-17
IE800638L (en) 1980-10-02
AT373577B (en) 1984-02-10
ES490166A0 (en) 1981-04-01
LU82316A1 (en) 1980-12-16
NL8001675A (en) 1980-10-06
NO150360B (en) 1984-06-25
ZA801527B (en) 1981-03-25
ES8104200A1 (en) 1981-04-01
DE3012140A1 (en) 1980-10-23
PH22024A (en) 1988-05-13
IE49653B1 (en) 1985-11-13
CH645092A5 (en) 1984-09-14
IT1147332B (en) 1986-11-19
GB2045771A (en) 1980-11-05
GB2045771B (en) 1983-01-26
BE882601A (en) 1980-10-02
NO150360C (en) 1984-10-03
DK140480A (en) 1980-10-03

Similar Documents

Publication Publication Date Title
NZ193142A (en) Mercaptoacylpeptides and pharmaceutical compositions
US4154960A (en) Amino acid derivatives
US4761399A (en) Dipeptide compounds having pharmaceutical activity and compositions containing them
JP3205558B2 (en) New peptide derivatives
US4596819A (en) Modified tripeptides
AU683658B2 (en) Substituted azepino (2,1-a) isoquinoline compounds
US4692458A (en) Anti-hypertensive agents
EP0007477B1 (en) 1-(3-mercapto-2-methylpropanoyl)prolyl amino acid derivatives and salts thereof, processes for their preparation, and pharmaceutical compositions containing such compounds
CZ129694A3 (en) Novel peptide derivatives
CS237311B2 (en) Processing of carboxyalkyldipeptide
CZ69094A3 (en) Heterocyclic inhibitors of farnesylprotein transferase
CA2155448A1 (en) Inhibitors of farnesyl protein transferase
IE48072B1 (en) Derivatives of dehydrocyclicimino acids
EP0253190B1 (en) Partially retro-inverted tuftsin analogues, method for the preparation thereof and pharmaceutical compositions containing them
WO1988006890A1 (en) Synthetic inhibitors of mammalian collagenase
JPS617295A (en) Mercaptocycloalkylcarbonyl and mercaptoaryl carbonyldipeptides
US4684660A (en) Mercaptoacyldepeptides
US4165320A (en) Amino acid derivatives
US4179434A (en) Amino acid derivatives
EP0036713B1 (en) Angiotensin converting enzyme inhibitors
US4293481A (en) Tripeptide inhibitors of angiotensin-converting enzyme
US4734420A (en) Anti-hypertensive agents
US4833152A (en) Anti-hypertensive agents
US4284779A (en) Amino acid derivatives
US4690936A (en) Anti-hypertensive agents